Navigation Links
BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
Date:11/15/2007

with the PARP inhibitor BSI-201," said Joyce O'Shaughnessy, M.D., lead investigator, Texas Oncology, PA, Baylor-Sammons Cancer Center in Dallas, US Oncology, and co-chair of the breast cancer research committee of the US Oncology Research Network. "There is a compelling need for a novel approach to treating this high-risk population."

The Phase 2 trial of BSI-201 in patients with triple-negative breast cancer will enroll 120 women in a multicenter, randomized, open-label trial that will compare standard chemotherapy with or without the addition of BSI- 201.

The research presented in Brussels showed the results of an analysis of PARP gene expression in 169 infiltrating ductal breast cancers through the use of the Gene Logic Inc. (Nasdaq: GLGC) BioExpress(R) System database. PARP expression was above the 99.9 percent upper confidence limit for normal tissue in 45 percent of all breast tumors, compared with 75 percent of breast tumors that were estrogen-negative and progesterone-negative and 90 percent of HER2- negative patients.

PARP is a well-characterized and validated target for cancer therapies. PARP plays a central role in cell proliferation in DNA repair, and the PARP-1 gene is upregulated in certain tumor types.

BiPar's novel, proprietary PARP inhibitors are a new generation of drug candidates that show promising activity and a favorable toxicity profile. Preclinical and early clinical studies suggest the drugs selectively induce tumor cell death and are active against a broad range of tumor types. In addition to the trial in patients with triple-negative breast cancer, BiPar plans to begin a series Phase1b and Phase 2 trials of BSI-201 in other major cancers that overexpress PARP over the next
'/>"/>

SOURCE BiPar Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
2. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
5. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
6. Enrollment Begins on Human PK Study for Medidur(TM) FA
7. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
8. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
9. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
10. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
11. DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
(Date:1/14/2014)... /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - a ... to place and insert the screw accurately - offers ... ligament) repair or reconstruction as it holds the bones ... http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC Screw ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, Inc. , ... modifying therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... to Valhalla, NY as of ... laboratory space at New York Medical College. ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... , MADISON, N.J., Nov. 18 Quest Diagnostics Incorporated ... testing, information and services, today announced that the Simplexa Influenza A ... CE marked and is now available as a test kit for ... the test at MEDICA 2009, November 18 to 21, 2009, at ...
... , NASHVILLE, Tenn., Nov. 17 Emdeon (NYSE: EM ... solutions, today announced that it will participate in the Piper Jaffray ... 2, 2009 in New York. , The "fireside chat", featuring Tracy ... Tuesday, December 1, 2009. A live audio webcast will be ...
Cached Medicine Technology:2009 H1N1 Flu Test From Quest Diagnostics Now CE Marked For International Distribution Under The Simplexa(TM) Brand Name 22009 H1N1 Flu Test From Quest Diagnostics Now CE Marked For International Distribution Under The Simplexa(TM) Brand Name 32009 H1N1 Flu Test From Quest Diagnostics Now CE Marked For International Distribution Under The Simplexa(TM) Brand Name 42009 H1N1 Flu Test From Quest Diagnostics Now CE Marked For International Distribution Under The Simplexa(TM) Brand Name 5
(Date:4/23/2014)... accessible detection methods that can rapidly screen a ... single cell inside that population has been seriously ... , In the Royal Society of Chemistry journal ... he and his coworkers have developed a novel ... protein ( Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, ...
(Date:4/23/2014)... health benefits of probiotics, antioxidants and other nutritional compounds, ... chemical industry is getting in on the action. But ... so the industry is responding with clinical research to ... in Chemical & Engineering News (C&EN), the ... Melody M. Bomgardner, a senior editor at C&EN, writes ...
(Date:4/23/2014)... In a country as wealthy as the United States, it ... do not have access to adequate food due to lack ... , Recent research at the University of Illinois using ... revealed that the seniors who are dealing with hunger are ... 2011, 8.35 percent of Americans over age 60 faced the ...
(Date:4/23/2014)... researcher from the Cancer Science Institute of Singapore (CSI ... the cancer specific stem cell which causes gastric cancer. ... drugs for the treatment of this disease and other ... Dr Chan Shing Leng, Research Assistant Professor at CSI ... variant of a cell surface protein, CD44v8-10, marks gastric ...
(Date:4/23/2014)... of Midlife Occupational and Leisure Time Physical Activity on ... activity in midlife increases the risk of mobility limitation ... risk. This is found in a study which followed ... study was conducted at the Gerontology Research Center in ... Heavy physical labor is often repetitive, wears the body ...
Breaking Medicine News(10 mins):Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... June 19 Agingcare.com, the online,community for caregivers, ... Carol Bradley-Bursack has joined the staff and will ... community portion of the website is where caregivers ... support, using discussion,boards. Publisher Joe Buckheit said, "We ...
... Inc. (NYSE: BKD ) announced today that management ... Jefferies Healthcare,Conference in New York, New York on Tuesday, ... presentation is being webcast live and can be accessed ... http://www.brookdaleliving.com . A replay of the webcast will be ...
... Radiosurgery System Offers Non-Invasive Treatment Alternative for ... Tumors Anywhere ... (Nasdaq: ARAY ), a global leader in the field ... Welfare (MHLW),has granted Shonin approval of the CyberKnife(R) Robotic Radiosurgery,System ...
... annual revenues and eight locations in New Jersey, ... Connecticut, and Pennsylvania -, LOUISVILLE, ... leading regional provider of home health nursing,services, today announced that it ... Inc. This acquisition, the Company,s,largest to date, expands Almost Family,s presence ...
... and LOS ANGELES, June 19 Cardo Medical,LLC, ... medical devices,and clickNsettle.com, Inc. (OTC Bulletin Board: CKST), ... a merger agreement pursuant,to which Cardo Medical will ... merger is completed, clickNsettle will be renamed,Cardo Medical, ...
... Care" Message to Fans, TALLAHASSEE, Fla., June 19 ... the top-ranked Florida Marlins and Tampa Bay,Rays are leading ... Tobacco Free Florida, an initiative of the Florida Department ... reach Floridians with,its messages of smoking and smokeless tobacco ...
Cached Medicine News:Health News:Agingcare.com Adds Elder Care Expert Carole Bursack to Staff 2Health News:Japan Approves CyberKnife System for Extracranial Use 2Health News:Japan Approves CyberKnife System for Extracranial Use 3Health News:Japan Approves CyberKnife System for Extracranial Use 4Health News:Almost Family, Inc. Signs Definitive Agreement to Acquire Patient Care, Inc. 2Health News:Almost Family, Inc. Signs Definitive Agreement to Acquire Patient Care, Inc. 3Health News:Almost Family, Inc. Signs Definitive Agreement to Acquire Patient Care, Inc. 4Health News:clickNsettle.com, Inc. and Cardo Medical, LLC Announce Merger Agreement 2Health News:clickNsettle.com, Inc. and Cardo Medical, LLC Announce Merger Agreement 3Health News:Rivalry Aside, Marlins and Rays Team Up To Fight Tobacco 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: